Aethlon Medical, Inc. (AEMD)

US — Healthcare Sector
Peers: APDN  BBLG  CTSO  GOVX  NNVC  OPGN  TIVC  TLIS  VIVE 

Automate Your Wheel Strategy on AEMD

With Tiblio's Option Bot, you can configure your own wheel strategy including AEMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AEMD
  • Rev/Share 0.0829
  • Book/Share 1648.7607
  • PB 0.0004
  • Debt/Equity 0.1676
  • CurrentRatio 2.4891
  • ROIC -0.0021

 

  • MktCap 1875560.0
  • FreeCF/Share -828.7525
  • PFCF -0.0011
  • PE -0.1191
  • Debt/Assets 0.1082
  • DivYield 0
  • ROE -0.0146

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed AEMD H.C. Wainwright -- Neutral -- $1.5 July 7, 2025

News

Aethlon Medical Announces Pricing of $4.5 Million Public Offering
AEMD
Published: September 04, 2025 by: PRNewsWire
Sentiment: Neutral

SAN DIEGO , Sept. 4, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 5,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.90 per share (or pre-funded warrant) and accompanying warrant.

Read More
image for news Aethlon Medical Announces Pricing of $4.5 Million Public Offering
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
AEMD
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral

Aethlon Medical invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO , Feb. 13, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 19, 2025.

Read More
image for news Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
Aethlon Medical, Inc. (AEMD) Q3 2025 Earnings Call Transcript
AEMD
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q3 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Jim Frakes – Chief Executive Officer Steven LaRosa – Chief Medical Officer Conference Call Participants Marla Marin – Zacks Anthony Vendetti – Maxim Group Operator Good day, and welcome to the Aethlon Medical Third Quarter Fiscal 2025 Earnings and Corporate Update Call. All participants will be in a listen-only mode.

Read More
image for news Aethlon Medical, Inc. (AEMD) Q3 2025 Earnings Call Transcript

About Aethlon Medical, Inc. (AEMD)

  • IPO Date 1999-03-04
  • Website https://www.aethlonmedical.com
  • Industry Medical - Devices
  • CEO James B. Frakes
  • Employees 14
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.